Streetbeat News

Regulatory

BABA

JD

NIO

PDD

US-listed Chinese companies' shares are rising due to strong stimulus efforts and better-than-expected September PMI data, despite a decline in factory activity.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 11:59 am

ALT

Altimmune has completed patient enrollment for its Phase 2B trial of pemvidutide in treating MASH, with results expected in Q2 2025. An FDA meeting for its obesity program is set for November 2024, and the company plans to submit IND applications for additional indications in late 2024.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 11:38 am

BBIO

BridgeBio Pharma has completed enrollment for its Phase 3 FORTIFY study of BBP-418, targeting Limb-girdle Muscular Dystrophy Type 2I/R9. Topline data from the interim analysis is expected in 2025.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 11:34 am

BHVN

Biohaven has initiated a pivotal Phase 2 study for its TRPM3 antagonist, BHV-2100, aimed at treating acute migraines. The trial will assess the efficacy and safety of two doses and is designed to support FDA registration.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 11:34 am

TRAW

Traws Pharma announced positive Phase 1 results for its COVID-19 candidate, Ratutrelvir, an oral inhibitor. The drug was well-tolerated and achieved consistent plasma levels without ritonavir. Phase 2a study is expected in H1 2025.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 11:32 am

MMC

Marsh McLennan (NYSE:MMC) is set to acquire McGriff Insurance Services for $7.75 billion, enhancing its capabilities in various insurance sectors. The deal is expected to close by year-end, pending regulatory approval.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 11:31 am

DXR

Daxor has decided to withdraw its current dual 510(k)/CLIA-Waiver application after discussions with the FDA and will resubmit a focused 510(k) application.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 11:29 am

MRNA

Moderna has initiated the dosing of the first US participant in the Nova 301 Phase 3 trial for its investigational norovirus vaccine, mRNA-1403. The trial aims to evaluate the vaccine's efficacy, safety, and immunogenicity, with global recruitment now underway.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 11:23 am

NRXP

NRx Pharmaceuticals (NASDAQ:NRXP) has achieved a key milestone with the 12-month stability of its drug NRX-100, indicating a shelf life of over three years. The company is on track to file a New Drug Application (NDA) in 2024.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 11:17 am

RDHL

RedHill Biopharma Ltd. (NASDAQ:RDHL) has secured a new U.S. patent for a COVID-19 treatment biomarker, valid through 2041. The patent is based on data showing opaganib's efficacy in treating COVID-19, including reduced mortality and improved patient outcomes. Opaganib is a broad-acting drug with potential applications in various diseases.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 11:03 am